Journal Mobile Options
Table of Contents
Vol. 84, No. 3, 2013
Issue release date: January 2013

A and B Blood Group Antigens in Human Pancreatic Ductal Adenocarcinomas

Handra-Luca A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: The aim of this study was to determine the clinicopathological significance of blood group expression patterns in patients with surgically resected pancreatic ductal adenocarcinomas. Methods: Pancreatic ductal adenocarcinomas from 459 patients were analyzed for immunohistochemical expression of A and B blood group antigens on tissue microarrays. Correlations were established by Fisher’s test, χ2 test, and logistic regression models, and relationships to postsurgical overall survival were analyzed by Kaplan-Meier method, log-rank test, and multivariate Cox models. Results: Tumors expressing blood group A antigen predicted fewer lymph node metastases (<3) and had longer postoperative survival by univariate and multivariate analysis. Loss of A antigen tumor expression in A blood group type patients correlated to vascular invasion. Conclusion: In patients with resectable pancreatic ductal adenocarcinomas, blood group A antigen expression predicted fewer lymph node metastases and was associated with improved outcome after pancreaticoduodenectomy.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al: Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009;41:986–990.
  2. Greer JB, Yazer MH, Raval JS, et al: Significant association between ABO blood group and pancreatic cancer. World J Gastroenterol 2010;16:5588–5591.
  3. Bosman FT, Carneiro F, Hruban RH, et al: WHO Classification of Digestive Tumors, ed 4. Lyon, IARC Press, 2010.
  4. Iodice S, Maisonneuve P, Botteri E, et al: ABO blood group and cancer. Eur J Cancer 2010;46:3345–3350.
  5. Maisonneuve P, Iodice S, Löhr JM, et al: Re: ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009;101:1156.
  6. Nakao M, Matsuo K, Hosono S, et al: ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. Cancer Sci 2011;102:1076–7080.
  7. Saadat M: Re: ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009;101:1285–1286.
  8. Vioque J, Walker AM: Pancreatic cancer and ABO blood types: a study of cases and controls (in Spanish). Med Clin (Barc) 1991;96:761–764.
  9. Wolpin BM, Chan AT, Hartge P, et al: ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009;101:424–431.
  10. Wolpin BM, Kraft P, Xu M, et al: Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. Cancer Epidemiol Biomarkers Prev 2010;19:3140–3149.
  11. Hakomori S: Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta 1999;1473:247–266.
  12. Schuessler MH, Pintado S, Welt S, et al: Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type 1, Tn and sialyl-Tn in pancreas cancer. Int J Cancer 1991;47:180–187.
  13. Ernst C, Thurin J, Atkinson B, et al: Monoclonal antibody localization of A and B isoantigens in normal and malignant fixed human tissues. Am J Pathol 1984;117:451–461.
  14. Itzkowitz SH, Yuan M, Ferrell LD, et al: Cancer-associated alterations of blood group antigen expression in the human pancreas. J Natl Cancer Inst 1987;79:425–434.
  15. Pour PM, Tempero MM, Takasaki H, et al: Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient’s blood group type. Cancer Res 1988;48:5422–5426.
  16. Stachura J, Tomaszewska R, Pietroń M: Blood groups antigens distribution in pancreatic cancer. An immunohistochemical study. Folia Histochem Cytobiol 1989;27:49–55.
  17. Takasaki H, Uchida E, Tempero MA, et al: Correlative studies on antigenicity of pancreatic cancer and blood group types. Cancer Detect Prev Suppl 1987;1:145–148.

    External Resources

  18. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds): AJCC Cancer Staging Manual, ed 7. New York, Springer, 2010.
  19. McShane LM, Altman DG, Sauerbrei W, et al; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: Reporting recommendations for neoplastic marker prognostic studies. J Clin Oncol 2005;23:9067–9072.
  20. Handra-Luca A, Hong SM, Walter K, et al: Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas. Br J Cancer 2011;104:1296–1302.
  21. Infante JR, Matsubayashi H, Sato N, et al: Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319–325.
  22. Davidsohn I, Ni LY, Stejskal R: Tissue isoantigens A, B, and H in carcinoma of the pancreas. Can Res 1971;31:1244–1250.
  23. Tomioka T, Fujii H, Egami H, et al: Correlation between morphology and blood group-related antigen expression in pancreatic tumors induced in Syrian hamsters. Carcinogenesis 1991;12:441–447.
  24. Chen CH, Wang PC: Diagnostic plots in Cox’s regression model. Biometrics 1991;47:841–850.
  25. Christensen E: Multivariate survival analysis using Cox’s regression model. Hepatology 1987;7:1346–1358.
  26. Hosmer DW, Lemeshow S: Applied Logistic Regression, ed 2. New York, Wiley, 2000.
  27. Ichikawa D, Handa K, Hakomori S: Histo-blood group A/B antigen deletion/reduction vs. continuous expression in human tumor cells as correlated with their malignancy. Int J Cancer 1998;76:284–289.
  28. Davidsohn I: Early immunologic diagnosis and prognosis of carcinoma. Philip Levine Award Address. Am J Clin Pathol 1972;57:715–730.
  29. Hirota M, Mogaki M, Pour PM, et al: Modification of blood group A antigen expression in a pancreatic cell line (PC-1) by inhibitors of N-glycam processing. J Cell Biochemistry 1992;50:13–20.
  30. Pour PM, Uchida E, Burnett DA, et al: Blood-group antigen expression during pancreatic cancer induction in hamsters. Int J Pancreatol 1986;1:327–340.
  31. Egami H, Tomioka T, Tempero M, et al: Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters. Am J Pathol 1991;138:557–561.
  32. Greer JB, LaRusch J, Brand RE, et al; NAPS2 Study Group: ABO blood group and chronic pancreatitis risk in the NAPS2 cohort. Pancreas 2011;40:1188–1194.
  33. Melzer D, Perry JR, Hernandez D, et al: A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 2008;4:e1000072.
  34. Paré G, Chasman DI, Kellogg M, et al: Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet 2008;4:e1000118.
  35. Denk H, Tappeiner G, Davidovits A, et al: Carcinoembryonic antigen and blood group substances in carcinomas of the stomach and colon. J Natl Cancer Inst 1974;53:933–942.
  36. Breimer ME: Tissue specificity of glycosphingolipids as expressed in pancreas and small intestine of blood group A and B human individuals. Arch Biochem Biophys 1984;228:71–85.
  37. Hakomori S: Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001;491:369–402.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50